Clement Arthur, Amar Edouard, Clement Patrice, Sedbon Éric, Brami Charles, Alvarez Silvia, Menezo Yves
Laboratoire Clément, Genetics and IVF, Avenue d'Eylau, Paris, France.
Cabinet Médical Urology, Andrology, Avenue Victor Hugo, Paris, France.
Front Reprod Health. 2023 Aug 29;5:1229997. doi: 10.3389/frph.2023.1229997. eCollection 2023.
Homocysteine (Hcy) is a cellular poison, side product of the hydrolysis of S-Adenosyl Homocysteine, produced after the universal methylation effector S -Adenosylmethionine liberates a methyl group to recipient targets. It inhibits the methylation processes and its rising is associated with multiple disease states and ultimately is both a cause and a consequence of oxidative stress, affecting male gametogenesis. We have determined hyper homocysteinhemia (HHcy) levels can be reliably reduced in hypofertile patients in order to decrease/avoid associated epigenetic problems and protect the health of future children, in consideration of the fact that treatment with high doses of folic acid is inappropriate.
Homocysteine levels were screened in male patients consulting for long-standing infertility associated with at least three failed Assisted Reproductive Technology (ART) attempts and/or repeat miscarriages. Seventy-seven patients with Hcy levels > 15 µM were treated for three months with a combination of micronutrients including 5- MethylTetraHydroFolate (5-MTHF), the compound downstream to the MTHFR enzyme, to support the one carbon cycle; re-testing was performed at the end of a 3 months treatment period. Genetic status for Methylenetetrahydrofolate Reductase (MTHFR) Single nucleotide polymorphisms (SNPs) 677CT (c.6777C > T) and 1298AC (c.1298A > C) was determined.
Micronutrients/5-MTHF were highly efficient in decreasing circulating Hcy, from averages 27.4 to 10.7 µM, with a mean observed decrease of 16.7 µM. The MTHFR SNP 677TT (homozygous form) and combined heterozygous 677CT/1298AC status represent 77.9% of the patients with elevated Hcy.
Estimation HHcy should not be overlooked in men suffering infertility of long duration. MTHFR SNPs, especially 677TT, are a major cause of high homocysteinhemia (HHcy). In these hypofertile patients, treatment with micronutrients including 5-MTHF reduces Hcy and even allows spontaneous pregnancies post treatment. This type of therapy should be considered in order to ensure these patients' quality of life and avoid future epigenetic problems in their descendants.
同型半胱氨酸(Hcy)是一种细胞毒素,是S-腺苷同型半胱氨酸水解的副产物,在通用甲基化效应物S-腺苷甲硫氨酸将甲基释放给受体靶点后产生。它会抑制甲基化过程,其水平升高与多种疾病状态相关,最终既是氧化应激的原因也是结果,会影响男性配子发生。考虑到高剂量叶酸治疗不合适,我们已确定可以可靠地降低不育患者的高同型半胱氨酸血症(HHcy)水平,以减少/避免相关的表观遗传问题并保护未来儿童的健康。
对因长期不育前来咨询的男性患者进行同型半胱氨酸水平筛查,这些患者至少有三次辅助生殖技术(ART)尝试失败和/或反复流产。对77名Hcy水平>15 μM的患者用包括5-甲基四氢叶酸(5-MTHF)在内的多种微量营养素组合治疗三个月,5-MTHF是亚甲基四氢叶酸还原酶(MTHFR)下游的化合物,用于支持一碳循环;在3个月治疗期结束时重新检测。确定了亚甲基四氢叶酸还原酶(MTHFR)单核苷酸多态性(SNP)677CT(c.6777C>T)和1298AC(c.1298A>C)的基因状态。
多种微量营养素/5-MTHF在降低循环Hcy方面非常有效,平均水平从27.4 μM降至10.7 μM,平均下降16.7 μM。MTHFR SNP 677TT(纯合形式)和复合杂合677CT/1298AC状态占Hcy升高患者的77.9%。
对于长期不育的男性,不应忽视HHcy的评估。MTHFR SNPs,尤其是677TT,是高同型半胱氨酸血症(HHcy)的主要原因。在这些不育患者中,用包括5-MTHF在内的多种微量营养素治疗可降低Hcy,甚至使治疗后自然受孕成为可能。应考虑这种治疗方式,以确保这些患者的生活质量并避免其后代未来出现表观遗传问题。